Tacrolimus to Belatacept Conversion Following Hand Transplantation: A Case Report
Linda C. Cendales(Emory University), Allan D. Kirk(University of Calgary), Luke P. Brewster(House of Representatives), Thomas C. Pearson(Emory Healthcare), David Farthing(Children's Healthcare of Atlanta), Howard M. Gebel(Rush University Medical Center), Arthur E. Stillman(Emory Healthcare), Rivka Elbein(Emory University), Minjung Song(Emory University), Douglas Parker(Emory University), Robert A. Bray(Emory University)
Cited by 39
Related Papers
Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
|Nature|1996|1.5k
Banff 2013 Meeting Report: Inclusion of C4d-Negative Antibody-Mediated Rejection and Antibody-Associated Arterial Lesions
|American Journal of Transplantation|2014|1.3k
4-1BB Costimulatory Signals Preferentially Induce CD8+ T Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses
|The Journal of Experimental Medicine|1997|802
Consensus Guidelines on the Testing and Clinical Management Issues Associated With HLA and Non-HLA Antibodies in Transplantation
|Transplantation|2012|777
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|714